Clinical Trial Update: Phase 1 Study of Anti-glycation Agent GLY-230 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial of GLY-230, an anti-glycation agent, completed in healthy subjects. Diabetes is listed as the related condition and the sponsor is Glycadia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes

Drugs mentioned

• GLY-230

Snippet

Sponsor: Glycadia | Conditions: Diabetes | Phase 1 | Status: COMPLETED